Comparative Pharmacology
Head-to-head clinical analysis: PARCOPA versus STALEVO 150.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARCOPA versus STALEVO 150.
PARCOPA vs STALEVO 150
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbidopa inhibits decarboxylation of levodopa in the periphery, increasing levodopa availability to the brain. Levodopa is converted to dopamine in the CNS, replenishing dopamine levels in the striatum.
Stalevo 150 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its bioavailability. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa.
0.5 mg orally three times daily, titrated slowly based on response and tolerability; maximum 8 mg/day.
One tablet orally three times daily. Each tablet contains 150 mg levodopa, 37.5 mg carbidopa, and 200 mg entacapone.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3 hours; in elderly patients, half-life may be prolonged due to reduced renal clearance, requiring dose adjustment.
Levodopa (with carbidopa): ~1.5-2 hours. Carbidopa: ~1-2 hours. Entacapone: ~0.4-0.7 hours (short half-life; not primary determinant of dosing interval). Clinically, levodopa half-life determines dosing frequency for motor fluctuations.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Carbidopa and levodopa are primarily excreted renally. Levodopa: ~70-80% renal, with metabolites including 3-O-methyldopa. Carbidopa: ~50-70% renal, with ~30% fecal. Entacapone: ~90% fecal (mainly as metabolites), ~10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent